The Jun N-terminal kinase (JNK) subgroup of the mitogenactivated protein kinase (MAPK) superfamily is implicated in multiple signaling pathways of critical physiological processes, including apoptosis, differentiation and proliferation. 1 Stressinduced JNK activation leads to cell death through activation of the mitochondrial apoptotic pathway in many cell types and also to the interferon-alpha-induced apoptosis in B-cell lymphoma. 2 Some JNK member such as JNK1 can also promote the survival of BCR/ABL-transformed leukemia cells 3 and is required for the survival and proliferation of B-lymphoma cells. 4 Frequent loss of heterozygosity (LOH) at specific chromosomal regions in human malignancies indicates the presence of candidate tumor suppressor genes (TSG) within the affected regions. Loss of heterozygosity on the long arm of chromosome 4 (4q) has been frequently reported in several tumors, including hematopoietic malignancies. 5, 6 We have applied high-resolution (1 Mb) array-comparative genomic hybridization (CGH) 7 to detect genetic changes in 27 tumor cell lines (seven lymphoma and 20 carcinoma cell lines), and identified a deletion at 4q21.3 in two esophageal carcinoma cell lines (Figure 1a) . Two proapoptotic proteins, MAPK10 (JNK3) and PTPN13 (PTPL1, FAP-1), a protein tyrosine phosphatase, are located within the deleted region, and share a 633-bp bidirectional promoter which is a typical CpG island (Figure 1b) . However, both genes were not directly affected by the deletion.
We further found that, in a total of 82 tumor cell lines, the expression of these two genes was frequently downregulated or silenced in non-Hodgkin's lymphoma (94%, 15 of 16), Hodgkin's lymphoma (50%, three of six), breast (30%, three of 10), gastric (60%, six of 10) and heptacellular (67%, eight of 12) carcinoma cell lines (Figure 1c ), whereas no downregulation was detected in other carcinoma cell lines examined (Figure 1e ). In contrast, in all human normal tissues (including lymph node and peripheral blood mononuclear cell samples), both MAPK10 and PTPN13 were ubiquitously expressed, although at different levels (Figure 1c and d) . Tumor suppressor genes can be inactivated through genetic or epigenetic mechanism, or a combination of both mechanisms. As no homozygous deletion of both genes was found in all the cell lines examined, we speculated that their silencing might be mediated through epigenetic mechanism. We analyzed the methylation status of their bidirectional promoter by methylationspecific PCR (Table 1) 8 . Methylation was detected invirtually all the cell lines with reduced or silenced expression, and in some cell lines, methylation completely silenced the expression of both genes (Figure 1c) , which was further confirmed by high-resolution bisulfite genomic sequencing analysis 7 ( Figure 1f ). Treatment with the demethylating agent 5-aza-2 0 -deoxycitidine (Aza) induced robust expression of both MAPK10 and PTPN13 in methylated cell lines (Figure 1g ), indicating that methylation directly mediates their silencing. We also observed that in rare cell lines without MAPK10 expression, no methylation was detected, indicating that other mechanisms such as transcriptional repressors might also be infrequently involved.
We further evaluated the tumor suppressor function of MAPK10 by transfecting MAPK10-expressing plasmid into silenced tumor cells. 7 This ectopic expression of MAPK10 dramatically suppressed the colony formation of breast carcinoma cells (Figure 1h ), directly indicating that MAPK10 does function as a TSG.
MAPK10 (JNK3) is a member of the JNK subgroup of MAP kinase implicated in important physiological processes, including apoptosis. 9, 10 Frequent loss of expression but no mutation of MAPK10 in brain tumors has been reported, and MAPK10 (JNK3) has been suggested as a class-II TSG being inactivated epigenetically. 11 In JNK3-deficient mice, the JNK3 signaling pathway mediates cell apoptosis of the central nervous system. 9 Disruption of JNK in murine fibroblasts resulted in the loss of tumor suppression in Ras-transformed cells, and the JNK Letters to the Editor pathway contributes to the elimination of transformed cells through apoptosis in vivo. 12 PTPN13 also induces Fas-independent apoptosis in breast cancer cells, through the phosphatidylinositol3-kinase/Akt pathway, 13 and its mutations have been detected in tumors.
14 Thus, our results together with previous studies suggest that both MAPK10 (JNK3), different from other Letters to the Editor JNK member (JNK1, JNK2), 4 and PTPN13 have proapoptotic functions and can function as TSGs to suppress tumorigenesis. However, their tumor suppressor functions were frequently disrupted epigenetically in multiple lymphomas and carcinomas owing to the methylation of their shared bidirectional promoter (Figure 1i ).
Myeloproliferative disorders (MPD) are chronic clonal proliferations of hematopoietic progenitors. Typical MPDs include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IF). Oncogenic alterations identified so far in MPDs target tyrosine kinases, result from chromosomal translocations or gene mutations and lead to constitutive activation of survival and proliferation pathways. Reciprocal translocations lead to gene fusion and production of chimeric proteins such as BCR-ABL, ETV6-PDGFRB or PCM1-JAK2.
1,2 Point mutations of the JAK2 kinase occur in almost all PV, and in around half of ET and IF.
3 JAK2 functions downstream of membrane receptors, including cytokine receptors such as interleukin-3 (IL3) receptors. Overproduction of IL3 has been reported in atypical CML following rearrangements of the IL3 gene upstream region in cells from patients with t(5;12)(q23-31;p13) translocation and ETV6-ACSL6 fusion. [4] [5] [6] [7] We report here two cases of t(5;12)(q23-31;p13) translocation with ETV6-ACSL6 rearrangement in PV patients. The main characteristics of the two patients (designated C1, C2) are reported in Table 1 , along with the cases reported so far. [4] [5] [6] [7] Patient C1, a 29-year-old man, presented in October 2002 with midly enlarged liver and spleen, effort dyspnea, and polycythemia with 59.7% hematocrit level. The bone marrow (BM) was hypercellular, with rare dystrophic megakaryocytes and 6% eosinophils, without basophilia. Isotopic exploration showed an increased total red blood cell mass. Cytogenetic analysis with R-banding technique on BM cells detected a t(5;12)(q23-31;p13) translocation in three metaphases among 24 analyzed (13%) ( Table 1 ). The patient was treated by phlebotomy but dyspnea persisted, and prurit, paresthesia and headaches appeared. Three months later, a treatment by hydroxyurea was started. Bone marrow showed dystrophic megakaryocytes of the PV type. In May 2005, BM analysis showed increased eosinophilia (16%) and basophilia (10%), and on karyotype, four metaphases among 20 (20%) showed the t(5;12) translocation. In January 2006, 3.5 years after diagnosis, the patient is alive under hydroxyurea treatment, the white blood cell count is 9.6 Â 10 9 /l with 15% eosinophils and 15% basophils, hemoglobin level 16.5 and platelet count 484 Â 10 9 /l. The indication of allogenic transplantation is under discussion.
Patient C2, a 31-year-old woman, presented in 1979 with PV. She was treated by phlebotomy and splenic irradiation. In 1998, because of an important splenomegaly, a second splenic
